FMR1, Blocking Peptide

Fragile X mental retardation protein 1; FMRP; Protein FMR-1; FMR1

For Research Use Only. Not for use in diagnostic procedures.

The synthetic peptide sequence used to generate the antibody was selected from the N-term region of human FMR1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.

Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C.

Small volumes of FMR1 blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Translation repressor. Component of the CYFIP1-EIF4E- FMR1 complex which binds to the mRNA cap and mediates translational repression. In the CYFIP1-EIF4E-FMR1 complex this subunit mediates translation repression (By similarity). RNA- binding protein that plays a role in intracellular RNA transport and in the regulation of translation of target mRNAs. Associated with polysomes. May play a role in the transport of mRNA from the nucleus to the cytoplasm. Binds strongly to poly(G), binds moderately to poly(U) but shows very little binding to poly(A) or poly(C).

58,835 Da

fragile X mental retardation 1

synaptic functional regulator FMR1

Synaptic functional regulator FMR1

Protein FMR-1  [Similar Products]

FMR1_HUMAN

The protein encoded by this gene binds RNA and is associated with polysomes. The encoded protein may be involved in mRNA trafficking from the nucleus to the cytoplasm. A trinucleotide repeat (CGG) in the 5' UTR is normally found at 6-53 copies, but an expansion to 55-230 repeats is the cause of fragile X syndrome. Expansion of the trinucleotide repeat may also cause one form of premature ovarian failure (POF1). Multiple alternatively spliced transcript variants that encode different protein isoforms and which are located in different cellular locations have been described for this gene. [provided by RefSeq, May 2010]

FMR1: Translation repressor. Component of the CYFIP1-EIF4E- FMR1 complex which binds to the mRNA cap and mediates translational repression. In the CYFIP1-EIF4E-FMR1 complex this subunit mediates translation repression. RNA- binding protein that plays a role in intracellular RNA transport and in the regulation of translation of target mRNAs. Associated with polysomes. May play a role in the transport of mRNA from the nucleus to the cytoplasm. Binds strongly to poly(G), binds moderately to poly(U) but shows very little binding to poly(A) or poly(C). Component of the CYFIP1-EIF4E-FMR1 complex which is composed of CYFIP, EIF4E and FMR1. Interacts with CYFIP1 and CYFIP2. The interaction with brain cytoplasmic RNA 1 (BC1) increases binding affinity for the CYFIP1-EIF4E complex in the brain. Homooligomer. Found in a RNP granule complex with IGF2BP1. Directly interacts with SMN and TDRD3. Interacts with the SMN core complex that contains SMN1, GEMIN2/SIP1, DDX20/GEMIN3, GEMIN4, GEMIN5, GEMIN6, GEMIN7, GEMIN8 and STRAP/UNRIP. Interacts with FXR1, FXR2, IGF2BP1, NUFIP1, NUFIP2, MCRS1 and RANBP9. Highest levels found in neurons, brain, testis, placenta and lymphocytes. Also expressed in epithelial tissues and at very low levels in glial cells. Belongs to the FMR1 family. 8 isoforms of the human protein are produced by alternative splicing.

Protein type: Translation; Nucleolus; RNA-binding

Chromosomal Location of Human Ortholog: Xq27.3

Cellular Component: axon; cell projection; chromocenter; chromosome; cytoplasm; dendrite; dendritic spine; extrinsic to plasma membrane; filopodium tip; growth cone; membrane; mRNA cap complex; nerve terminal; neuron projection; nucleolus; nucleoplasm; nucleus; perikaryon; perinuclear region of cytoplasm; polysomal ribosome; polysome; postsynaptic density; ribonucleoprotein complex; SMN complex; synapse

Molecular Function: chromatin binding; dynein binding; identical protein binding; methylated histone residue binding; microtubule binding; miRNA binding; mRNA 3'-UTR binding; mRNA 5'-UTR binding; mRNA binding; poly(rG) binding; poly(U) binding; protein binding; protein heterodimerization activity; protein homodimerization activity; ribosome binding; RNA binding; RNA strand annealing activity; siRNA binding; translation initiation factor binding; translation repressor activity

Biological Process: glutamate signaling pathway; mRNA transport; negative regulation of translation; negative regulation of translational initiation; positive regulation of filopodium formation; positive regulation of histone phosphorylation; positive regulation of receptor internalization; positive regulation of translation; regulation of alternative nuclear mRNA splicing, via spliceosome; regulation of filopodium formation; regulation of mRNA stability; regulation of neurotransmitter secretion; response to DNA damage stimulus

Disease: Fragile X Mental Retardation Syndrome; Fragile X Tremor/ataxia Syndrome; Premature Ovarian Failure 1

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.